Michelle Lockley
@mlockley.bsky.social
Medical oncologist and scientist, into all things ovarian cancer. In search of the answer to cancer drug resistance
Oops, here you go: aacrjournals.org/cancerres/ar...
Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control
Abstract. Drug resistance results in poor outcomes for cancer patients. Adaptive therapy is a potential strategy to address drug resistance that exploits competitive interactions between sensitive and...
aacrjournals.org
May 2, 2025 at 1:14 PM
Oops, here you go: aacrjournals.org/cancerres/ar...
Reposted by Michelle Lockley
This means "adaptive therapy" where chemo dose is reduced when the tumour responds well could be a route to long-term tumour control for ovarian cancer (for certain disease types and stages). @mlockley.bsky.social is testing this in the ACTOv clinical trial: bmjopen.bmj.com/content/14/1...
Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on cha...
Introduction Adaptive ChemoTherapy for Ovarian cancer (ACTOv) is a phase II, multicentre, randomised controlled trial, evaluating an adaptive therapy (AT) regimen with carboplatin in women with relaps...
bmjopen.bmj.com
May 2, 2025 at 12:50 PM
This means "adaptive therapy" where chemo dose is reduced when the tumour responds well could be a route to long-term tumour control for ovarian cancer (for certain disease types and stages). @mlockley.bsky.social is testing this in the ACTOv clinical trial: bmjopen.bmj.com/content/14/1...